Paris-based biotech firm Phagos has raised €25 million in a Collection A funding spherical co-led by CapAgro, Hoxton Ventures, CapHorn and Demeter, with extra participation from Acurio Ventures, Citizen Capital, Entrepreneur First, Founders Capital and Station F. The corporate, based in 2021 by Alexandros Pantalis and Dr Adèle James, develops bacteriophage-based therapies, a pure various to antibiotics, and holds the primary authorisation to market personalised phage-based veterinary remedies within the EU.
The brand new funding will assist the deployment of veterinary remedies, additional improvement of Phagos’ patented AI know-how for phage discovery, and the corporate’s worldwide growth throughout Europe, Asia and the Americas.
Phagos’ strategy tackles one of the vital urgent challenges in world well being: bacterial resistance. Bacterial infections are at present the world’s second main reason for human mortality and a significant reason for animal deaths. In addition they contribute to important meals waste and financial losses. Antimicrobial resistance already causes tens of millions of deaths yearly and will value the worldwide economic system as much as $100 trillion by 2050. In livestock, one in three antibiotics is not efficient, a threefold enhance from 2000.
By combining microbiology and synthetic intelligence, Phagos’ platform can design ultra-precise and personalised phage-based remedies to fight bacterial ailments. Its preliminary focus is on animal well being, focusing on infections reminiscent of Salmonella and E. coli, with the long-term goal of extending its options to human well being.
Phagos’ regulatory approval marks a major milestone, making it the primary firm worldwide authorised to market personalised phage-based veterinary medication. The corporate has additionally filed a patent for its AI know-how, which might analyse the whole genomes of each phages and micro organism to foretell their interactions. This functionality permits Phagos to make phage remedy scalable, focused and efficient.
With this new funding, Phagos plans to broaden its veterinary phage remedy options, strengthen its R&D efforts and scale the following technology of its AI discovery know-how. The corporate is already collaborating with main trade gamers in subject deployments and intends to proceed its world growth. Its staff, at present composed of 90% scientific and technical professionals, may also develop to assist market launches and product improvement.
“We’re satisfied that phage remedy can rework the historical past of drugs simply as antibiotics did within the final century. This funding offers us the means to speed up our mission and make this various accessible, quick, and efficient towards the rise of bacterial resistance. Because of our regulatory breakthroughs and our patented platform combining microbiology and synthetic intelligence, we now have the chance to determine phage remedy as a worldwide reference answer: for animal well being as we speak, and for human well being tomorrow,” stated Alexandros Pantalis and Adèle James, co-founders of Phagos.
“Antimicrobial resistance is a defining problem for world meals methods. With the unprecedented regulatory approval of its discovery platform, Phagos is main the best way in deploying phage therapies as an actual, already actionable various to antibiotics. Our funding in Phagos underscores our robust dedication to deep tech improvements that drive a more healthy, extra sustainable, and resilient meals provide,” stated Anne-Valérie Bach, Managing Director of Capagro.
“Phagos’ pioneering platform offers a high-efficiency various to antibiotics, providing a promising answer to a significant world well being disaster. This funding will assist the corporate turn into a category-defining chief, reshaping how bacterial infections are handled with a transformative impression on each animal and human well being in an enormous world market,” added Rob Kniaz, Founder and Emeritus Associate of Hoxton Ventures.
